Share-based Payment Arrangement, Expense of MARINUS PHARMACEUTICALS, INC. from 31 Mar 2014 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
MARINUS PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2014 to 30 Sep 2024.
  • MARINUS PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2024 was $4,830,000, a 21% increase year-over-year.
  • MARINUS PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2024 was $18,865,000, a 20% increase year-over-year.
  • MARINUS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $15,563,000, a 4.5% increase from 2022.
  • MARINUS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $14,890,000, a 9.6% increase from 2021.
  • MARINUS PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2021 was $13,588,000, a 82% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

MARINUS PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $18,865,000 $4,830,000 +$824,000 +21% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $18,041,000 $4,917,000 +$1,026,000 +26% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $17,015,000 $5,193,000 +$1,452,000 +39% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $15,563,000 $3,925,000 -$175,000 -4.3% 01 Oct 2023 31 Dec 2023 10-K 05 Mar 2024 2023 FY
Q3 2023 $15,738,000 $4,006,000 +$111,000 +2.8% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $15,627,000 $3,891,000 +$74,000 +1.9% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $15,553,000 $3,741,000 +$663,000 +22% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $14,890,000 $4,100,000 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $3,895,000 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $3,817,000 +$907,000 +31% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $3,078,000 -$1,902,000 -38% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q2 2021 $2,910,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $4,980,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q2 2016 $738,000 +$350,000 +90% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2016 2016 Q2
Q1 2016 $739,000 +$356,000 +93% 01 Jan 2016 31 Mar 2016 10-Q 02 May 2016 2016 Q1
Q3 2015 $597,000 +$381,000 +176% 01 Jul 2015 30 Sep 2015 10-Q 29 Oct 2015 2015 Q3
Q2 2015 $388,000 +$364,000 +1517% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $383,000 +$360,000 +1565% 01 Jan 2015 31 Mar 2015 10-Q 02 May 2016 2016 Q1
Q3 2014 $216,000 01 Jul 2014 30 Sep 2014 10-Q 29 Oct 2015 2015 Q3
Q2 2014 $24,000 01 Apr 2014 30 Jun 2014 10-Q 04 Aug 2015 2015 Q2
Q1 2014 $23,000 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1

MARINUS PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $15,563,000 +$673,000 +4.5% 01 Jan 2023 31 Dec 2023 10-K 05 Mar 2024 2023 FY
2022 $14,890,000 +$1,302,000 +9.6% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $13,588,000 +$6,129,000 +82% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $7,459,000 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.